Public Accounts committee  Not really.... When we were preparing the first launch, we faced a quality problem. We decided not to release an out-of-specification product, certainly.

Public Accounts committee  Yes.

Public Accounts committee  The parts that were redacted in our access to information response in February 2021 was information relating to pricing, quantity, facility locations and availability plans. We thought this had a direct commercial application. That is the reason why we requested the redaction of those documents.

Public Accounts committee  It was pricing, facility locations and the quantities, which is the key information that should not be utilized by our competitors.

Public Accounts committee  Thank you very much for the question. If I caught it correctly, the question was why we would have intellectual property in the contract.

Public Accounts committee  It is a product of many years of investment, but we did not prohibit, in the contract, the government reselling the vaccine. If necessary, they have the licensing rights to use our intellectual property, so the vaccine, for pandemic preparedness, can be produced domestically in Canada.

Public Accounts committee  Medicago owns it, currently.

Public Accounts committee  Thank you very much. Ladies and gentlemen, I would like to thank this committee for inviting me to attend with the panel of witnesses today. My name is Toshifumi Tada, president and CEO of Medicago since May 2022. Before that, I was a director of the board for Medicago for four years, representing Mitsubishi Tanabe Pharma, our majority shareholder.